CY1110589T1 - ΠΑΡΑΓΩΓΑ ΤΗΣ ΘΕΙΕΝΟ(2,3-b)ΠΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΤΗΣ ΟΡΜΟΝΗΣ ΑΠΕΛΕΥΘΕΡΩΣΕΩΣ ΓΟΝΑΔΟΤΡΟΠΟΥ ΟΡΜΟΝΗΣ - Google Patents

ΠΑΡΑΓΩΓΑ ΤΗΣ ΘΕΙΕΝΟ(2,3-b)ΠΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΤΗΣ ΟΡΜΟΝΗΣ ΑΠΕΛΕΥΘΕΡΩΣΕΩΣ ΓΟΝΑΔΟΤΡΟΠΟΥ ΟΡΜΟΝΗΣ

Info

Publication number
CY1110589T1
CY1110589T1 CY20101100121T CY101100121T CY1110589T1 CY 1110589 T1 CY1110589 T1 CY 1110589T1 CY 20101100121 T CY20101100121 T CY 20101100121T CY 101100121 T CY101100121 T CY 101100121T CY 1110589 T1 CY1110589 T1 CY 1110589T1
Authority
CY
Cyprus
Prior art keywords
hormone
antagonists
pyridine derivatives
sulphine
derivatives useful
Prior art date
Application number
CY20101100121T
Other languages
English (en)
Inventor
Zhihua Sui
Mark Macielag
James C Lanter
Original Assignee
Ortho-Mcneil-Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil-Janssen Pharmaceuticals, Inc. filed Critical Ortho-Mcneil-Janssen Pharmaceuticals, Inc.
Publication of CY1110589T1 publication Critical patent/CY1110589T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεσις αναφέρεται εις νέα παράγωγα 7-ετεροκυκλο κινολίνης και θειενο[2,3-b]πυριδίνης του γενικού τύπου (I) ή (II), εις τους οποίους όλαι αι μεταβληταί είναι ως καθορίζονται ενταύθα, φαρμακευτικαί συνθέσεις περιέχουσαι αυτά, και χρήσις των εις την θεραπείαν διαταραχών και καταστάσεων σχετιζομένων με την απελευθέρωσιν γοναδοτρόπου ορμόνης (GnRH). Αι ενώσεις της εφευρέσεως είναι ανταγωνισταί GnRH, χρήσιμοι εις την θεραπείαν της στειρότητος, καρκίνου προστάτου, καλοήθους υπερπλάσιας προστάτου (ΒΡΗ), και ως αντισυλληπτικά (φάρμακα).
CY20101100121T 2000-12-12 2010-02-09 ΠΑΡΑΓΩΓΑ ΤΗΣ ΘΕΙΕΝΟ(2,3-b)ΠΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΤΗΣ ΟΡΜΟΝΗΣ ΑΠΕΛΕΥΘΕΡΩΣΕΩΣ ΓΟΝΑΔΟΤΡΟΠΟΥ ΟΡΜΟΝΗΣ CY1110589T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25482700P 2000-12-12 2000-12-12
US09/992,785 US6583153B2 (en) 2000-12-12 2001-11-14 7-heterocyclyl quinoline and thieno[2,3-b]yridine derivatives useful as antagonists of gonadotropin releasing hormone
EP04078019A EP1520855B1 (en) 2000-12-12 2001-12-11 Thieno(2,3-b)pyridine derivatives useful as antagonists of gonadotropin releasing hormone

Publications (1)

Publication Number Publication Date
CY1110589T1 true CY1110589T1 (el) 2015-04-29

Family

ID=26944257

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20061101492T CY1105712T1 (el) 2000-12-12 2006-10-18 Παραγωγα 7-ετεροκυκλο κινολινης και θειενο[2,3-β] πυριδινης χρησιμα ως ανταγωνισται απελευθερωσεως γοναδοτροπου ορμονης
CY20101100121T CY1110589T1 (el) 2000-12-12 2010-02-09 ΠΑΡΑΓΩΓΑ ΤΗΣ ΘΕΙΕΝΟ(2,3-b)ΠΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΤΗΣ ΟΡΜΟΝΗΣ ΑΠΕΛΕΥΘΕΡΩΣΕΩΣ ΓΟΝΑΔΟΤΡΟΠΟΥ ΟΡΜΟΝΗΣ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20061101492T CY1105712T1 (el) 2000-12-12 2006-10-18 Παραγωγα 7-ετεροκυκλο κινολινης και θειενο[2,3-β] πυριδινης χρησιμα ως ανταγωνισται απελευθερωσεως γοναδοτροπου ορμονης

Country Status (14)

Country Link
US (2) US6583153B2 (el)
EP (2) EP1345907B1 (el)
JP (1) JP4427251B2 (el)
CN (1) CN1288137C (el)
AT (2) ATE337303T1 (el)
AU (2) AU2002229033B2 (el)
CA (1) CA2431617C (el)
CY (2) CY1105712T1 (el)
DE (2) DE60140700D1 (el)
DK (2) DK1520855T3 (el)
ES (2) ES2269499T3 (el)
HK (1) HK1055957A1 (el)
PT (2) PT1520855E (el)
WO (1) WO2002048112A2 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
TW200413351A (en) * 2002-08-21 2004-08-01 Astrazeneca Ab Chemical compounds
WO2004035541A1 (en) * 2002-10-15 2004-04-29 Janssen Pharmaceutica, N.V. Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators
CA2631917A1 (en) * 2005-12-05 2007-06-14 Merck & Co., Inc. Quinolone m1 receptor positive allosteric modulators
WO2011049731A1 (en) * 2009-10-21 2011-04-28 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
CN116239498B (zh) * 2023-05-11 2023-07-21 北京元延医药科技股份有限公司 制备克立硼罗中间体的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659691A (en) 1985-02-08 1987-04-21 Merck & Co., Inc. Novel cyclic Hexapeptide LHRH antagonists
US5140009A (en) 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
US5171835A (en) 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
US5607939A (en) 1994-04-28 1997-03-04 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
JPH10500402A (ja) 1994-04-29 1998-01-13 武田薬品工業株式会社 縮合複素環化合物またはその塩、その製造法および用途
WO1996038438A1 (en) 1995-06-01 1996-12-05 Takeda Chemical Industries, Ltd. TRICYCLIC DIAZEPINES USEFUL AS GnRH RECEPTOR ANTAGONISTS
DE69623655T2 (de) 1995-10-19 2003-04-24 Takeda Chemical Industries Ltd Chinolinderivate als gnrh antagonisten
AU7333396A (en) 1995-10-19 1997-05-07 Takeda Chemical Industries Ltd. Thienopyridine derivatives as gonadotropin releasing hormone antagonists
EP0871624A1 (en) 1995-12-14 1998-10-21 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CZ183198A3 (cs) 1995-12-14 1998-10-14 Merck And Co., Inc. Nepeptidové deriváty, antagonizující hormon, uvolňující gonadotropin a farmaceutický prostředek
EP0900222A1 (en) 1996-04-26 1999-03-10 Takeda Chemical Industries, Ltd. Thienopyridine derivatives, their production and use
CA2250908C (en) 1996-04-30 2012-03-13 Takeda Chemical Industries, Ltd. Combined use of gnrh agonist and antagonist
JP2000511532A (ja) 1996-05-20 2000-09-05 メルク エンド カンパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモンのアンタゴニスト
JP2000511182A (ja) 1996-05-20 2000-08-29 メルク エンド カンパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモンのアンタゴニスト
EP0920319A4 (en) 1996-05-20 2002-05-02 Merck & Co Inc GONADOLIBERIN ANTAGONISTS
AU706818B2 (en) 1996-05-20 1999-06-24 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
GB9610813D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of benzufuran derivatives

Also Published As

Publication number Publication date
WO2002048112A3 (en) 2002-08-22
EP1345907B1 (en) 2006-08-23
DE60122575T2 (de) 2007-09-13
JP4427251B2 (ja) 2010-03-03
HK1055957A1 (en) 2004-01-30
AU2903302A (en) 2002-06-24
EP1345907A2 (en) 2003-09-24
CN1288137C (zh) 2006-12-06
PT1520855E (pt) 2010-01-06
DE60140700D1 (de) 2010-01-14
ES2337898T3 (es) 2010-04-30
US20020123506A1 (en) 2002-09-05
US6583153B2 (en) 2003-06-24
US20030216429A1 (en) 2003-11-20
EP1520855A1 (en) 2005-04-06
PT1345907E (pt) 2006-11-30
JP2004515541A (ja) 2004-05-27
CA2431617C (en) 2011-07-12
CA2431617A1 (en) 2002-06-20
DK1520855T3 (da) 2010-03-15
EP1520855B1 (en) 2009-12-02
ATE337303T1 (de) 2006-09-15
DE60122575D1 (de) 2006-10-05
CY1105712T1 (el) 2010-12-22
AU2002229033B2 (en) 2007-09-13
ES2269499T3 (es) 2007-04-01
DK1345907T3 (da) 2006-11-13
WO2002048112A2 (en) 2002-06-20
ATE450510T1 (de) 2009-12-15
US6765011B2 (en) 2004-07-20
CN1489579A (zh) 2004-04-14

Similar Documents

Publication Publication Date Title
CY1110589T1 (el) ΠΑΡΑΓΩΓΑ ΤΗΣ ΘΕΙΕΝΟ(2,3-b)ΠΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΤΗΣ ΟΡΜΟΝΗΣ ΑΠΕΛΕΥΘΕΡΩΣΕΩΣ ΓΟΝΑΔΟΤΡΟΠΟΥ ΟΡΜΟΝΗΣ
PT1187918E (pt) Antagonistas de tek
AP1538A (en) Tricyclic inhibitors of poly (adp-ribose) polymerases.
PA8569501A1 (es) Compuestos utiles en terapia
EA200800067A1 (ru) Нестероидные антиандрогены, направленные на 12 спираль (рецептора андрогенов)
BR9711319A (pt) Derivados de camptotecina altamente lipofìlicos.
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
ATE253063T1 (de) 5-ht1f-agonisten
TR199801195T2 (xx) Tedavide yararl� kinolin ve kinozilin bile�ikleri.
HK1021699A1 (en) Pentafluorobenzenesulfonamides and analogs.
DE60309667D1 (de) Biphenylderivate und ihre verwendung als antiandrogene
AU3029297A (en) 7alpha-(5-methylaminopentyl)-estratrienes, process for their production, pharmaceutical preparations that contain these 7alpha-(5-methylaminopentyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
ATE557007T1 (de) Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen
PT916670E (pt) Pirrolo-(3,2-b) piridinas e o seu uso como agonistas do 5-ht1f
DE69911017D1 (en) Arylsulfonanilid-phosphate
WO2001030804A3 (en) Salt form of a conjugate useful in the treatment of prostate cancer
UY26498A1 (es) Pirroles sustituidos
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
BR0112147A (pt) Tienopirrolidinonas
ECSP982362A (es) Compuestos de quinolina y quinazolina utiles en terapia
CY1107334T1 (el) Μεθοδοι για την αναστολη της αγγειογενεσης
BR0207451A (pt) Derivados de quinolina, isoquinolina e ftalazina como antagonistas do hormÈnio liberador de gonadotropina
ATE339415T1 (de) Benzocarbazol und indenoindole derivate als östrogene agentien